Efficacy of Neoadjuvant Chemotherapy DOX and XELOX Regimens for Patients with Resectable Gastric or Gastroesophageal Junction Adenocarcinoma

Table 1

General clinical characteristics of patients in the three groups.

	DOX	XELOX	Surgery		value
Age (year)				1.520	0.468
<45	15	17	11
45-60	85	83	89
Sex				0.694	0.707
M	73	69	74
F	27	31	26
ECOG				0.770	0.681
0	38	42	44
1	62	58	56
Tumor center				5.768	0.450
EGJ	33	38	28
Gastric body	11	14	10
Gastric antrum	52	42	53
Other	4	6	9
Pathological type				2.362	0.669
High and medium differentiation	56	49	51
Poor differentiation	33	42	36
Very low differentiation	11	9	13
cT stage				1.510	0.470
cT3	28	31	36
cT4	72	69	64
cN stage				7.382	0.287
cN0	10	16	12
cN1	35	32	41
cN2	41	46	35
cN3	14	6	12
Borrmann type				9.769	0.135
I	3	0	0
II	35	39	31
III	55	56	66
IV	7	5	3

Very low differentiation: signet ring cell carcinoma, mucous adenocarcinoma, and anaplastic carcinoma.